2020-12-02

Camurus announces that Braeburn receives Complete Response Letter for Brixadi for opioid use disorder in the US

Camurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Brixadi.

Read the full press release: https://www.camurus.com/

Latest news

2018-12-07

Buvidal® Weekly and Buvidal® Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence

Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company’s lead p…

Read more

2018-11-22

Camurus receives EU approval for Buvidal®

Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence. Buvidal® is the first…

Read more

2018-10-26

AF Bostäder has installed SWATAB's filter system

AF Bostäder in Lund will open two new laundry rooms at Vildanden, a student housing, where the students can wash wit…

Read more

2018-10-26

Camurus Interim Report January-September 2018

“Following the positive CHMP opinion for Buvidal®, we have ramped up our commercial activities and are ready for lau…

Read more

2018-07-20

Solo Rescue to spin-off from GRANULDISK

Sandberg Development has decided to spin-off and concentrate the business within the subsidiary GRANULDISK’s product…

Read more